Recent news reports highlight DarioHealth's quarterly financial results, including losses and revenue performance, as well as credit agreement amendments and ongoing operational challenges.

• DarioHealth reported a Q4 loss while noting revenue performance, reflecting ongoing financial challenges [N1].
• The company reported a Q3 loss with revenue below expectations but noted a decrease in loss compared to prior periods [N4][N5].
• In November 2025, DarioHealth amended its credit agreement to reset financial covenants, modify liquidity requirements, and adjust warrant terms, indicating active liquidity management [S2].
• The company faces supply chain delays and increased costs due to tariffs and trade policy changes, impacting hardware sourcing and project timelines [S2].
• Market price volatility has been significant, influenced by external factors and company-specific developments [S2].

The company has demonstrated liquidity management through credit agreement amendments and maintains a cash buffer relative to liabilities. Recent quarterly results show some reduction in losses and revenue performance that may indicate operational adjustments. The company's presence in digital health and medical devices positions it in a growing sector with potential for strategic partnerships or product development.

DarioHealth faces significant geopolitical risks due to its operations in Israel, including exposure to regional conflicts and military instability. The company reported substantial net losses and faces supply chain challenges related to tariffs and trade policies, which have caused project delays and increased costs. Market price volatility and external economic factors add uncertainty to its financial stability. The lack of detailed business model disclosures and ongoing losses present risks to sustained operations and investor confidence.

DarioHealth's moat is not explicitly detailed in public disclosures. The company operates in a competitive healthcare technology space with exposure to supply chain and geopolitical risks. Its ability to maintain liquidity and manage financing arrangements suggests some operational resilience, but the lack of detailed product differentiation or proprietary technology disclosures limits visibility into sustainable competitive advantages.

• Geopolitical and Regional Instability: Operations and executive officers located in Israel expose the company to risks from ongoing conflicts, military actions, and political instability, which could disrupt business operations and financial condition [S2].
• Supply Chain and Tariff Risks: Tariffs and trade policy changes have increased costs and caused delays in hardware sourcing and project execution, impacting margins and operational timelines [S2].
• Market Price Volatility: The company's stock price has experienced extreme fluctuations due to various factors including market conditions, stockholder activity, and external commentary, which may affect liquidity and valuation [S2].
• Financial Losses and Liquidity Management: The company reported a net loss of $41.7 million for fiscal 2025 and has amended credit agreements to manage liquidity and covenant requirements, indicating ongoing financial challenges [S1][S2].
• Regulatory and Legal Risks: Potential regulatory changes and legal proceedings could materially affect the company's business and financial results, as disclosed in risk factors [S1][S2].

• DarioHealth Corp. is a publicly traded company listed on The Nasdaq Capital Market under the ticker DRIO.
• The company filed a Form 10-K for the fiscal year ended December 31, 2025, on March 19, 2026, disclosing financial and operational information.
• As of December 31, 2025, DarioHealth reported cash and cash equivalents of $21.8 million and current assets of $35.1 million, with current liabilities of $9.3 million, resulting in a current ratio of 3.76 and a cash ratio of 2.8, indicating liquidity.
• The company reported a net loss of $41.7 million for the fiscal year ended December 31, 2025, and basic and diluted earnings per share of $10.12, as disclosed in the 10-K filing.
• DarioHealth's business operations and executive officers are partly located in Israel, exposing the company to geopolitical risks including regional conflicts and military instability, as detailed in risk disclosures.
• The company faces risks related to U.S. trade policies and tariffs, which have impacted hardware sourcing and project timelines, with some medical devices and components manufactured in China.
• The market price of DarioHealth's common stock has experienced significant volatility, influenced by factors such as stockholder activity, analyst commentary, and broader market conditions.
• In November 2025, DarioHealth amended its credit agreement, including resetting financial covenants and modifying liquidity requirements, indicating active management of financing arrangements.
• Recent quarterly reports indicate the company has reported losses but has shown some improvement in loss reduction in Q3 2025 and reported a Q4 loss with revenue performance noted in public news.
• The company has disclosed risks related to potential disruptions from geopolitical events, supply chain challenges, and regulatory developments affecting its business and financial condition.